Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Ventana Paves the Way for High-Standard Companion Diagnostic Clinical Trials Services in China

By LabMedica International staff writers
Posted on 12 Aug 2014
Ventana Medical Systems, Inc. More...
(Tucson, AZ, USA), member of the Roche Group, has announced a new agreement with Quintiles, Inc. (Durham, NC, USA) to offer College of American Pathology (CAP)-standard companion diagnostic testing services to cancer patients in China via early phase clinical trials conducted by pharmaceutical and biotech companies. This is good news for patients as China is one of the only countries in the world that requires all patient samples be tested in China, even those used in clinical trials. And incorporating a companion diagnostic strategy into a drug development program is more likely to help develop more effective drugs with improved safety profiles for patients.

"Our new relationship with Quintiles to offer companion diagnostic testing services in China moves our mission, to improve the lives of all patients afflicted with cancer, a big step forward," said Doug Ward, vice president and Companion Diagnostics Lifecycle leader, Ventana, "Our oncology pharma collaborators can now reach a large and growing number of patients that can benefit from clinical trial participation using targeted treatments and tests."

According to the World Health Organization (WHO)'s latest World Cancer Report, in 2012 China had the highest rate of new cancer cases recorded globally, 3.07 million (21.9%), and the trend is increasing, particularly in lung, liver, esophageal, and stomach cancers. This underscores the growing need for patients in China to have in-country access to the most advanced tissue diagnostic testing and companion therapeutics in the industry, which starts with early phase clinical trials.

"It's been extremely important to Ventana that we find a strategic laboratory in China that will help us uphold the CAP testing standard of excellence set by our global companion diagnostic CAP/CLIA laboratory in Tucson, Arizona, USA," said Dr. H. James Hnatyszyn, Ventana director of Laboratory Operations for companion diagnostics, "Quintiles has the experience, infrastructure, and qualified personnel to meet this challenge."

Early phase clinical trial testing according to the rigorous CAP standards set by Ventana is now available.

Related Links:
Ventana Medical Systems
Quintiles



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.